Question 1

What are the potential benefits of participating in this trial compared to standard treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia clinical trial (NCT02612311). Contact the study team or your healthcare provider for specific answers.

Question 2

How do the side effects of the new treatments compare to those of the standard treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia clinical trial (NCT02612311). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the treatment schedule look like, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia clinical trial (NCT02612311). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any specific risks associated with the new treatments being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia clinical trial (NCT02612311). Contact the study team or your healthcare provider for specific answers.

Question 5

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia clinical trial (NCT02612311). Contact the study team or your healthcare provider for specific answers.

What this study is about